CareDx Inc (CDNA) reports a 21% revenue increase and raises 2025 guidance amid innovation and operational improvements.

CareDx (CDNA) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.14 per share a year ago. These figures are ...

For the quarter ended September 2025, CareDx (CDNA) reported revenue of $100.06 million, up 20.7% over the same period last year. EPS came in at $0.28, compared to $0.14 in the year-ago quarter. The ...

The upcoming report from CareDx (CDNA) is expected to reveal quarterly loss of $0.19 per share, indicating a decline of 72.7% compared to the year-ago period. Analysts forecast revenues of $63.63 ...

CareDx (CDNA) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- ...

CareDx is estimated to be 35% overvalued based on current share price of US$14.35 Our fair value estimate is 51% lower than CareDx's analyst price target of US$21.83 Today we'll do a simple run ...

BRISBANE, Calif. (AP) — BRISBANE, Calif. (AP) — CareDx Inc. (CDNA) on Tuesday reported profit of $1.7 million in its third quarter. The Brisbane, California-based company said it had profit of 3 cents ...

Craig-Hallum analyst Alexander Nowak maintained a Hold rating on CareDx (CDNA – Research Report) today. The company’s shares closed yesterday at $9.64. Nowak covers the Healthcare sector, focusing on ...

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions ...

Craig-Hallum analyst William Bonello maintained a Buy rating on CareDx (CDNA – Research Report) today. The company’s shares closed last Friday at $22.64. Bonello covers the Healthcare sector, focusing ...